Robert F Coniff

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

Robert F Coniff, J. Shapiro, Timothy B. Seaton et al. · The American Journal of Medicine · 1995 · 181 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +10

Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison study

Robert F Coniff, JoAnn Shapiro, David C. Robbins et al. · Diabetes Care · 1995 · 134 citations

Advantages of α-Glucosidase Inhibition as Monotherapy in Elderly Type 2 Diabetic Patients

Peter Johnston, Harold E. Lebovitz, Robert F Coniff et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 129 citations · Full text

Effects of the Carbohydrase Inhibitor Miglitol in Sulfonylurea-Treated NIDDM Patients

Peter Johnston, Robert F Coniff, Byron J. Hoogwerf et al. · Diabetes Care · 1994 · 108 citations

A Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of Acarbose for the Treatment of Patients With Insulin-Requiring Type II Diabetes

Robert F Coniff, J. Shapiro, Timothy B. Seaton et al. · Diabetes Care · 1995 · 91 citations